Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Plos One|November 14, 2014
Clonal architectures and driver mutations in metastatic melanomasLi Ding, Minjung Kim, Krishna L Kanchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2022
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant MelanomaJanice M Mehnert, Tara C Mitchell, Alexander C Huang, et al.
The Lancet. Oncology|September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialF Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Cancer Research Communications|June 28, 2023
Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast CarcinomaPayal D Shah, Alexander C Huang, Xiaowei Xu, et al.
Cancer Cell|December 13, 2022
Expression of inducible factors reprograms CAR-T cells for enhanced function and safetyAnže Smole, Alexander Benton, Mathilde A Poussin, et al.
Blood|June 18, 2013
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaGerald P Linette, Edward A Stadtmauer, Marcela V Maus, et al.
Journal of Cancer Research and Clinical Oncology|December 7, 2016
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanomaThomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, et al.
Cancer Cell|February 21, 2025
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer modelsPatrizia Porazzi, Siena Nason, Ziqi Yang, et al.
The Lancet. Oncology|March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialJeffrey S Weber, Sandra P D'Angelo, David Minor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaRobert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
Pageof 8